Pricing & Sizes
Ships sealed and lyophilized — stable for years at room temperature, supplied as lyophilised powder. Free shipping on every order, no minimum. Every batch ships with its lab report. Reports come from third-party labs including Janoshik, Freedom Diagnostics and Chromate, most verifiable through the lab's own public portal. Ask and we will send the report for your batch.
Lab report on file. Current batch tested by Freedom Diagnostics — HPLC-UV + MS. Verifiable through the lab's public portal; ask and we will send it.
Reconstitution — bacteriostatic water: 70mg vial reconstituted at 3mL gives 23.3mg/mL. These are concentrations, calculated from vial content and diluent volume. They describe the solution, not a dose.
Bought separately, GHK-Cu 50mg ($35) plus BPC-157 10mg ($48) is $83. GLOW is $100, so the extra 10mg of TB-500 costs $17 — and TB-500 is not sold on its own.
Email To OrderAlso Available in These Blends
In Plain English
GHK-Cu is a small copper-carrying peptide that occurs naturally in human plasma and declines steadily with age. It has been used in skincare for decades and has the most credible research base of anything in this blend. Adding it to the recovery pairing is aimed at the visible side of repair — skin quality, hair, connective tissue — rather than the joint and tendon side alone.
What people use it for. The cosmetic side of repair — skin quality, fine lines, hair, and general tissue recovery. It is the blend people choose when appearance matters as much as joint function.
What to know before you buy. GHK-Cu is the standout component and has the best research behind it of anything in this range, but most of that research is on creams applied to skin rather than injection — worth knowing, because the two are often conflated in marketing. The solution will be deep blue from the copper; that is normal and not a fault. Note also that GHK-Cu has not yet had its FDA review, which is expected sometime before the end of February 2027.
What It's Studied For
| Research area | What that rests on |
|---|---|
| Skin elasticity research | GHK-Cu has controlled human topical studies reporting improved firmness and elasticity |
| Collagen support | GHK-Cu stimulates collagen and glycosaminoglycan production in skin fibroblasts |
| Hair support | A smaller but real body of GHK-Cu follicle research |
| Recovery underneath it | The BPC-157 and TB-500 base, same as Wolverine |
The left column lists the research areas this compound is investigated in; the right column states what that rests on. These are published research findings, not proven outcomes or treatment claims, and nothing here is a recommendation. Sold for laboratory research use only.
At a Glance
- Components
- GHK-Cu, BPC-157 and TB-500
- Rationale
- Skin and connective tissue support (GHK-Cu) layered onto the two-peptide recovery base
- GHK-Cu evidence
- The strongest of the three — substantial published dermatological and wound-healing literature, including human topical studies
- Regulatory (US)
- No component is FDA-approved. BPC-157 and TB-500 were recommended for 503A listing 23 July 2026 with no FDA action since; GHK-Cu was not on that agenda
- GHK-Cu track
- Scheduled for a separate PCAC meeting expected before the end of February 2027
- Format
- 70mg vial
Regulatory status
Two of the three components — BPC-157 and TB-500 — were recommended 8-6-1 for the 503A bulks list on 23 July 2026. That vote is advisory only. As of 17 August 2026 the FDA has taken no action on it, has not opened rulemaking, and has not moved the substance to the interim Category 1 list. FDA’s own scientific reviewers had recommended against all seven peptides; the committee voted against staff on six consecutive votes, so the usual assumption that a PCAC recommendation predicts the agency’s decision is weaker here than normal. GHK-Cu was not on that agenda and is queued for a separate PCAC meeting expected before the end of February 2027. Do not read the July outcome as covering the copper peptide component. Several outlets have reported this as the FDA “clearing”, “approving” or “adding” these peptides to the bulks list. That is inaccurate. Nothing has been added and nothing is legally cleared.
How the Components Compare
| Component | What it adds | What it does not do |
|---|---|---|
| GHK-Cu | The only component with controlled human studies. Brings collagen synthesis, skin firmness and hair support — the visible side the other two do not touch | Strongest evidence is topical rather than injectable. Does not target tendon or joint repair |
| BPC-157 | Adds the broad tissue-repair signal, including gut, which GHK-Cu does not provide | No skin firmness or collagen role. No completed human trial |
| TB-500 | Adds cell migration and tissue remodelling | No direct research of its own. Nothing for skin or inflammation |
Component Breakdown
| Component | What the research supports | Evidence strength |
|---|---|---|
| GHK-Cu | Collagen synthesis, wound healing, antioxidant activity, skin remodelling; human topical data exists | Strongest of the three |
| BPC-157 | Broad tissue repair signal across animal models | Deep animal base, near-absent human data |
| TB-500 | Inferred from Tβ4 rather than studied directly | Weakest of the three |
As with all blends here, the combination itself has not been studied. What you can reasonably say is that each component has an individual rationale; what you cannot say is that the combination has been shown to outperform any single component.
Two Regulatory Tracks, Not One
This is the practical point that most coverage gets wrong. GLOW straddles two separate FDA processes running on different timelines. The BPC-157 and TB-500 components sit behind a July 2026 recommendation awaiting agency action; GHK-Cu has not yet been reviewed at all. Neither is resolved, and they will not resolve together.
Section 503A permits a pharmacy to compound with a bulk substance only if it is a component of an approved drug, is subject to a USP monograph, or appears on the 503A bulks list. These peptides meet none of the three today. FDA removed them from Category 2 in April 2026 when the nominations were withdrawn, but as Polsinelli noted, Category 2 removal does not by itself confer Category 1 interim enforcement discretion.
The bottom line
The blend with the most credible single component. GHK-Cu’s dermatological literature is real and predates the current peptide wave by decades. The other two components carry the same caveats they carry everywhere else, and the copper peptide’s own regulatory review is still months away.